New Delhi, Aug 29 (PTI) Pharma major Lupin Ltd on Tuesday said it received approval from the US health regulator to market its generic Pirfenidone capsules used for the treatment of lung disease known as idiopathic pulmonary fibrosis.

The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Pirfenidone capsules of 267 mg strength, Lupin said in a regulatory filing.

Also Read | Indian Coast Guard Recruitment 2023: Vacancies Notified for 46 Assistant Commandant Posts, Apply Online at joinindiancoastguard.cdac.in.

The drug is the generic equivalent of Esbriet Capsules, 267 mg of Hoffmann La Roche Inc.

This product will be manufactured at Lupin's Pithampur facility in India, it added.

Also Read | Kerala Lottery Result Today 3 PM Live, Fifty-Fifty FF-63 Lottery Result of 29.08.2023, Watch Lucky Draw Winner List.

Pirfenidone capsules had estimated annual sales of USD 95 million in the US, Lupin said citing IQVIA MAT June 2023 data.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)